Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 18, 2021, Selecta Biosciences, Inc. (the "Company") held its Annual
Meeting of Stockholders. A total of 76,356,811 shares of the Company's common
stock were present electronically or represented by proxy at the meeting,
representing approximately 67.46% of the Company's outstanding common stock as
of the April 21, 2021 record date. The following are the voting results for the
proposals considered and voted upon at the meeting, all of which were described
in the Company's Definitive Proxy Statement filed with the Securities and
Exchange Commission on April 29, 2021.
Item 1 - Election of three Class II Directors to serve until the 2024 Annual
Meeting of Stockholders, and until their respective successors have been duly
elected and qualified.
NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes
Göran Ando, M.D. 53,398,234 8,034,027 14,924,550
Carrie S. Cox 53,388,481 8,043,780 14,924,550
Aymeric Sallin 45,267,262 16,164,999 14,924,550
Item 2 - Ratification of the appointment of Ernst & Young LLP as the Company's
independent registered public accounting firm for the year ending December 31,
2021.
Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes
76,269,773 50,628 36,410 -
Based on the foregoing votes, Göran Ando, M.D., Carrie S. Cox, and Aymeric
Sallin were elected as Class II Directors and Item 2 was approved.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses